Clinical Trials Browser

Osteosarcoma × Standard of Care × Clear all

Pathologic Complete Response, Bone Neoplasms, Chondrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Patient Compliance, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT03628209 2026-02-05

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Phase 1 Active not recruiting

21 enrolled

Sarcoma

Sarcoma, Osteosarcoma

Clinical Trials

REGOSTA

Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma